BD announces CFO transition and shares preliminary revenue results for fiscal 2025 with strong year-over-year growth.

BD (Becton, Dickinson and Company), a prominent global medical technology company, reported that Chris DelOrefice, the current executive vice president and CFO, will resign on December 5, 2025, to accept a new job offer. The company has already started looking for his replacement.

Following DelOrefice’s exit, Vitor Roque, the senior vice president of finance and corporate financial planning, will take over as interim CFO. He will work hand in hand with both the departing CFO and the senior management team to guarantee that there are no hiccups in the transition process.

BD’s Chairman, CEO, and President Tom Polen thanked DelOrefice for his role in shaping the BD 2025 strategy and offered to support Roque, who has spent almost 20 years in the company and has strong financial and leadership skills that will be very useful during the transition.

In connection with the CFO announcement, BD also issued preliminary fiscal 2025 results indicating that the fourth-quarter revenue was around $5.9 billion, which is an increase of 8.3% compared to the previous year. The revenue from the full year was $21.8 billion, which is an 8.2% increase on a reported basis. The company also anticipates that the adjusted diluted earnings per share will at least match the earlier guidance.

On November 6, 2025, BD will conduct an earnings webcast to elaborate on the financial results and share the company’s future expectations.